Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

X4 Pharmaceuticals stock price, quote, forecast and news

XFOR
US98420X1037
A2PFVY

Price

0.70
Today +/-
+0.00
Today %
+0.06 %
P

X4 Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the X4 Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the X4 Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the X4 Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze X4 Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

X4 Pharmaceuticals Stock Price History

DateX4 Pharmaceuticals Price
9/18/20240.70 undefined
9/17/20240.70 undefined
9/16/20240.66 undefined
9/13/20240.71 undefined
9/12/20240.68 undefined
9/11/20240.69 undefined
9/10/20240.69 undefined
9/9/20240.66 undefined
9/6/20240.65 undefined
9/5/20240.68 undefined
9/4/20240.68 undefined
9/3/20240.66 undefined
8/30/20240.70 undefined
8/29/20240.69 undefined
8/28/20240.69 undefined
8/27/20240.70 undefined
8/26/20240.73 undefined
8/23/20240.75 undefined
8/22/20240.76 undefined
8/21/20240.77 undefined

X4 Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into X4 Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by X4 Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects X4 Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of X4 Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into X4 Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing X4 Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on X4 Pharmaceuticals’s growth potential.

X4 Pharmaceuticals Revenue, EBIT and net profit per share

DateX4 Pharmaceuticals RevenueX4 Pharmaceuticals EBITX4 Pharmaceuticals Net Income
2029e365.66 M undefined0 undefined84.22 M undefined
2028e209.56 M undefined20.16 M undefined15.47 M undefined
2027e186.72 M undefined-7.91 M undefined343,740 undefined
2026e103.49 M undefined-69.48 M undefined-43.54 M undefined
2025e44.93 M undefined-108.26 M undefined-80.29 M undefined
2024e6.45 M undefined-127.88 M undefined-36.34 M undefined
20230 undefined-107.52 M undefined-101.17 M undefined
20220 undefined-88.08 M undefined-96.41 M undefined
20210 undefined-75.35 M undefined-102.64 M undefined
20203 M undefined-59.88 M undefined-62.13 M undefined
20190 undefined-46.8 M undefined-53.4 M undefined
20183.5 M undefined-45.89 M undefined-43.02 M undefined
20170 undefined-36.14 M undefined-33.92 M undefined
20160 undefined-24.34 M undefined-23 M undefined
20150 undefined-14.83 M undefined-13.24 M undefined

X4 Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
000303000644103186209365
----------633.33134.0980.5812.3774.64
---------------
000000000000000
-14-24-36-45-46-59-75-88-107-127-108-69-7200
----1,500.00--1,966.67----2,116.67-245.45-66.99-3.769.57-
-13-23-33-43-53-62-102-96-101-36-80-4301584
-76.9243.4830.3023.2616.9864.52-5.885.21-64.36122.22-46.25--460.00
1.81.82.382.3811.5320.0825.7563.53177.81000000
---------------
Details

Keystats

ⓘ

Revenue and Growth

The X4 Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the X4 Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201520162017201820192020202120222023
                 
6.8376.830.8126.278.781.8121.7114.22
000000000
000000000
000000000
0.11.31.11.51.13.75.35.87.3
6.94.377.932.3127.382.487.1127.5121.51
0.80.50.40.32.49.210.28.36.4
000000000
000000000
000000000
000027.127.117.417.417.35
0.41.41.30.61.93.31.71.21.44
1.21.91.70.931.439.629.326.925.18
8.16.279.633.2158.7122116.4154.4146.7
                 
29.939.8000000.10.17
0.41150.8156.6261.4267.1347.4450.8528.96
-35.4-58.4-92.3-135.3-132-194.2-282.9-376.7-477.91
700800100200-100-100-100-100-119
000000000
-4.4-16.858.621.5129.372.864.474.151.1
0.41.61.90.52.13.14.37.88.95
1.52.25.84.17.48.88.913.213.92
2.23.10.70.700000
2.22.90000000
0.32.32.30000.81.30
6.612.110.75.39.511.91422.322.86
4.710.19.97.920.133.233.132.354.57
000000000
2.52.11.91.11.94.95.626.918.73
7.212.211.892238.138.759.273.3
13.824.322.514.331.55052.781.596.16
9.47.581.135.8160.8122.8117.1155.6147.26
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of X4 Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand X4 Pharmaceuticals's financial health and stability.

Assets

X4 Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that X4 Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of X4 Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into X4 Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201520162017201820192020202120222023
-13-22-33-43-52-62-88-93-101
000000000
000000000
103-4-3-4-150
0237912241512
000012234
000000000
-10-21-27-40-48-58-70-77-96
00000-1000
000027-100-14
000027000-14
000000000
4123-40120020
75106014007412268
1118101-4140127411788
---8.00-----4.00-
000000000
0-373-45119-47239-22
-10.99-21.71-27.91-40.93-48.23-60.18-71.53-77.2-96.57
000000000

X4 Pharmaceuticals stock margins

The X4 Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of X4 Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for X4 Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the X4 Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the X4 Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the X4 Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the X4 Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the X4 Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the X4 Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the X4 Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

X4 Pharmaceuticals Margin History

X4 Pharmaceuticals Gross marginX4 Pharmaceuticals Profit marginX4 Pharmaceuticals EBIT marginX4 Pharmaceuticals Profit margin
2029e0 %0 %23.03 %
2028e0 %9.62 %7.38 %
2027e0 %-4.24 %0.18 %
2026e0 %-67.14 %-42.07 %
2025e0 %-240.97 %-178.7 %
2024e0 %-1,983.21 %-563.56 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %-1,996 %-2,071 %
20190 %0 %0 %
20180 %-1,311.14 %-1,229.14 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %

X4 Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The X4 Pharmaceuticals earnings per share therefore indicates how much revenue X4 Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue X4 Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates X4 Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of X4 Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating X4 Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

X4 Pharmaceuticals Revenue, EBIT and net profit per share

DateX4 Pharmaceuticals Sales per ShareX4 Pharmaceuticals EBIT per shareX4 Pharmaceuticals Earnings per Share
2029e2.17 undefined0 undefined0.5 undefined
2028e1.24 undefined0 undefined0.09 undefined
2027e1.11 undefined0 undefined0 undefined
2026e0.61 undefined0 undefined-0.26 undefined
2025e0.27 undefined0 undefined-0.48 undefined
2024e0.04 undefined0 undefined-0.22 undefined
20230 undefined-0.6 undefined-0.57 undefined
20220 undefined-1.39 undefined-1.52 undefined
20210 undefined-2.93 undefined-3.99 undefined
20200.15 undefined-2.98 undefined-3.09 undefined
20190 undefined-4.06 undefined-4.63 undefined
20181.47 undefined-19.28 undefined-18.08 undefined
20170 undefined-15.18 undefined-14.25 undefined
20160 undefined-13.52 undefined-12.78 undefined
20150 undefined-8.24 undefined-7.36 undefined

X4 Pharmaceuticals business model

X4 Pharmaceuticals Inc is a biopharmaceutical company founded in 2015 and based in Massachusetts. The company focuses on the discovery and development of new therapies for rare genetic diseases and cancer. X4 Pharmaceuticals is one of the most popular companies on Eulerpool.com.

X4 Pharmaceuticals SWOT Analysis

Strengths

X4 Pharmaceuticals Inc has a strong portfolio of innovative drug candidates in development.

The company has a talented and experienced research and development team.

X4 Pharmaceuticals Inc holds a robust intellectual property portfolio, providing a competitive advantage in the market.

Weaknesses

X4 Pharmaceuticals Inc is relatively new and has limited financial resources compared to larger pharmaceutical companies.

The company is heavily dependent on the success of its drug candidates in development.

X4 Pharmaceuticals Inc may face challenges in marketing and distributing its products due to its smaller size and limited resources in these areas.

Opportunities

There is a growing demand for innovative therapies in the pharmaceutical market.

X4 Pharmaceuticals Inc can leverage partnerships with larger pharmaceutical companies for funding and commercialization.

Expanding into emerging markets presents an opportunity for X4 Pharmaceuticals Inc to reach new patient populations and generate additional revenue.

Threats

The pharmaceutical industry is highly regulated and subject to stringent approval processes.

Competition from larger pharmaceutical companies with greater resources and established market presence poses a threat to X4 Pharmaceuticals Inc.

The company may face legal and intellectual property challenges from competitors, potentially impacting its competitive advantage.

X4 Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

X4 Pharmaceuticals historical P/E ratio, EBIT, and P/S ratio.

X4 Pharmaceuticals shares outstanding

The number of shares was X4 Pharmaceuticals in 2023 — This indicates how many shares 177.812 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue X4 Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates X4 Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of X4 Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating X4 Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

X4 Pharmaceuticals Stock splits

In X4 Pharmaceuticals's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for X4 Pharmaceuticals.

X4 Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20240.01 -0.07  (-1,306.9 %)2024 Q2
3/31/2024-0.17 -0.26  (-56.53 %)2024 Q1
12/31/2023-0.16 -0.1  (35.86 %)2023 Q4
9/30/2023-0.15 -0.01  (93.42 %)2023 Q3
6/30/2023-0.17 -0.33  (-98.08 %)2023 Q2
3/31/2023-0.22 -0.16  (27.77 %)2023 Q1
12/31/2022-0.25 -0.29  (-17.84 %)2022 Q4
9/30/2022-0.31 -0.26  (14.81 %)2022 Q3
6/30/2022-0.65 -0.6  (7.88 %)2022 Q2
3/31/2022-0.62 -0.72  (-16 %)2022 Q1
1
2
3

Eulerpool ESG Scorecard© for the X4 Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

55/ 100

🌱 Environment

59

👫 Social

66

🏛️ Governance

41

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

X4 Pharmaceuticals list of shareholders

%
Name
Stocks
Change
Date
8.89424 % New Enterprise Associates (NEA)14,986,793012/31/2023
4.75304 % The Vanguard Group, Inc.8,008,865184,14812/31/2023
4.61187 % BlackRock Institutional Trust Company, N.A.7,771,007260,68312/31/2023
4.23354 % OrbiMed Advisors, LLC7,133,515012/31/2023
2.53787 % Adage Capital Management, L.P.4,276,315012/31/2023
2.12963 % Sio Capital Management, LLC3,588,427989,42412/31/2023
2.10413 % Perceptive Advisors LLC3,545,454012/31/2023
2.06153 % Kingdon Capital Management, L.L.C.3,473,6831,500,00012/31/2023
10.03904 % Bain Capital Life Sciences Investors, LLC16,915,784955,19612/31/2023
1.82405 % AXA Investment Managers UK Ltd.3,073,532-74,33312/31/2023
1
2
3
4
5
...
10

X4 Pharmaceuticals Executives and Management Board

Dr. Paula Ragan53
X4 Pharmaceuticals President, Chief Executive Officer, Secretary, Director (since 2014)
Compensation 3.87 M
Mr. Adam Mostafa43
X4 Pharmaceuticals Chief Financial Officer, Treasurer, Corporate Secretary
Compensation 1.88 M
Dr. Mary Dibiase62
X4 Pharmaceuticals Chief Operating Officer
Compensation 1.84 M
Mr. Michael Wyzga68
X4 Pharmaceuticals Non-Executive Independent Chairman of the Board
Compensation 95,022
Mr. David Mcgirr68
X4 Pharmaceuticals Independent Director
Compensation 61,734
1
2
3

Most common questions regarding X4 Pharmaceuticals

What values and corporate philosophy does X4 Pharmaceuticals represent?

X4 Pharmaceuticals Inc represents a strong commitment to transforming the lives of patients through innovative therapies. With a focus on rare diseases and severe genetic disorders, the company aims to develop and commercialize treatments that address significant unmet medical needs. X4 Pharmaceuticals is driven by a core philosophy of scientific excellence, collaboration, and patient-centricity. By employing novel approaches and leveraging cutting-edge research, the company strives to deliver groundbreaking solutions that improve the quality of life for individuals facing challenging health conditions. With a strong emphasis on research and development, X4 Pharmaceuticals continues to pioneer advancements in the field of biotechnology.

In which countries and regions is X4 Pharmaceuticals primarily present?

X4 Pharmaceuticals Inc is primarily present in the United States.

What significant milestones has the company X4 Pharmaceuticals achieved?

X4 Pharmaceuticals Inc has achieved several significant milestones since its inception. Notably, the company successfully completed its initial public offering (IPO) in 2018, indicating investor confidence in its potential. Moreover, X4 Pharmaceuticals has made remarkable progress in the development of its lead candidate, X4P-001, for the treatment of various rare diseases. The company has initiated multiple clinical trials, showing promising results in the improvement of patients' condition. Additionally, X4 Pharmaceuticals has established strategic partnerships with renowned organizations to bolster research and development efforts further. These achievements highlight the commitment and expertise of X4 Pharmaceuticals Inc in advancing innovative therapies that address unmet medical needs.

What is the history and background of the company X4 Pharmaceuticals?

X4 Pharmaceuticals Inc is a leading biopharmaceutical company focused on developing innovative therapies for rare diseases and cancer. Founded in 2015, X4 Pharmaceuticals has quickly gained recognition for its novel approach to targeting the body's immune system and restoring its natural ability to fight diseases. The company's groundbreaking research and development efforts center around developing small molecule drugs that selectively modulate chemokine receptors, controlling cellular migration and activation. With a diverse pipeline of potential therapies, X4 Pharmaceuticals is committed to delivering breakthrough treatments and improving the lives of patients worldwide.

Who are the main competitors of X4 Pharmaceuticals in the market?

The main competitors of X4 Pharmaceuticals Inc in the market include companies such as Company A, Company B, and Company C. These companies compete with X4 Pharmaceuticals Inc in terms of developing and commercializing innovative pharmaceutical products. With its unique approach and strong product pipeline, X4 Pharmaceuticals Inc aims to differentiate itself and capture a significant market share in the pharmaceutical industry. However, the competitive landscape remains dynamic, and market conditions may change over time.

In which industries is X4 Pharmaceuticals primarily active?

X4 Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of X4 Pharmaceuticals?

X4 Pharmaceuticals Inc operates under a business model focused on developing targeted therapies for rare genetic diseases and cancer. By leveraging its proprietary platform, X4P-001, the company aims to address serious unmet medical needs and improve patients' lives. X4 Pharmaceuticals Inc's innovative approach targets chemokine receptors to modulate the immune system and restore normal cellular function. With a mission to bring transformative advancements in precision medicine, X4 Pharmaceuticals Inc is committed to advancing its pipeline of promising drug candidates through rigorous research, clinical development, and strategic partnerships.

What is the P/E ratio of X4 Pharmaceuticals 2024?

The X4 Pharmaceuticals P/E ratio is -3.44.

What is the P/S ratio of X4 Pharmaceuticals 2024?

The X4 Pharmaceuticals P/S ratio is 19.39.

What is the AlleAktien quality score of X4 Pharmaceuticals?

The AlleAktien quality score for X4 Pharmaceuticals is 2/10.

What is the revenue of X4 Pharmaceuticals 2024?

The expected X4 Pharmaceuticals revenue is 6.45 M USD.

How high is the profit of X4 Pharmaceuticals 2024?

The expected X4 Pharmaceuticals profit is -36.34 M USD.

What is the business model of X4 Pharmaceuticals

The X4 Pharmaceuticals Inc is a publicly traded biotechnology company from the USA that develops innovative therapies for rare diseases. The company is known for its groundbreaking research program in the field of immuno-oncology, inflammatory diseases, and primary immunodeficiencies. The X4 Pharmaceuticals Inc business model is based on the discovery, development, and commercialization of new drugs developed using new technologies. The company conducts research and development in collaboration with top academic institutions and independent laboratories. The company has various divisions, including research and development, production, and marketing. X4 Pharmaceuticals Inc focuses on the development of drugs targeting CXCR4 receptors. These are proteins responsible for controlling signals within the immune system. The company has developed several products, including X4P-001, a novel antibody therapeutic for cancer patients. X4P-001 targets CXCR4, a receptor that is overexpressed in many types of cancer and is considered responsible for disease progression. Another product that the company has developed is X4P-002. This medication is nearing clinical trials and is used for the treatment of primary immunodeficiencies and inflammatory diseases. X4P-002 has been recognized for its outstanding efficacy and tolerability in animal models. In addition to these products, X4 Pharmaceuticals Inc also has a comprehensive portfolio of patents to secure its technologies and products. The company has filed hundreds of patent applications for its drug candidates as well as its scientific research. X4 Pharmaceuticals Inc also operates production and business development units dedicated to reaching potential partners and investors for its technologies and drug candidates. By partnering with other pharmaceutical companies and scientific institutions, the company can expand and accelerate its product pipeline. Overall, the X4 Pharmaceuticals Inc business model is based on the discovery and development of new therapies for rare diseases through the exploration of novel technologies. The company aims to bring innovative and effective products to the market that can improve the lives of patients worldwide. With a dedicated and experienced leadership team and a team of experts in the field of biotechnology and medicine, X4 Pharmaceuticals Inc is on track to become one of the leading companies in the development of new drugs.

What is the X4 Pharmaceuticals dividend?

X4 Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does X4 Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for X4 Pharmaceuticals or the company does not pay out a dividend.

What is the X4 Pharmaceuticals ISIN?

The ISIN of X4 Pharmaceuticals is US98420X1037.

What is the X4 Pharmaceuticals WKN?

The WKN of X4 Pharmaceuticals is A2PFVY.

What is the X4 Pharmaceuticals ticker?

The ticker of X4 Pharmaceuticals is XFOR.

How much dividend does X4 Pharmaceuticals pay?

Over the past 12 months, X4 Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, X4 Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of X4 Pharmaceuticals?

The current dividend yield of X4 Pharmaceuticals is .

When does X4 Pharmaceuticals pay dividends?

X4 Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of X4 Pharmaceuticals?

X4 Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of X4 Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is X4 Pharmaceuticals located?

X4 Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von X4 Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of X4 Pharmaceuticals from 9/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/19/2024.

When did X4 Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/19/2024.

What was the dividend of X4 Pharmaceuticals in the year 2023?

In the year 2023, X4 Pharmaceuticals distributed 0 USD as dividends.

In which currency does X4 Pharmaceuticals pay out the dividend?

The dividends of X4 Pharmaceuticals are distributed in USD.

All fundamentals about X4 Pharmaceuticals

Our stock analysis for X4 Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of X4 Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.